 |
6 Diseases |  |
3 Trials |
|
3 Trials |  |
90 News |  |
| «12 |
- ||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P2 trial: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder (clinicaltrials.gov) - Feb 5, 2018
P2, N=150, Recruiting, Sponsor: Avanir Pharmaceuticals
- deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment change, Trial termination: Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition (clinicaltrials.gov) - Jan 23, 2018
P2, N=1, Terminated, Sponsor: Avanir Pharmaceuticals
N=12 --> 1 | Recruiting --> Terminated; The study was terminated prematurely because of difficulty with recruiting.
- |||||||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P3 trial: Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Jan 8, 2018
P3, N=412, Recruiting, Sponsor: Avanir Pharmaceuticals
- |||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial primary completion date: Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Jan 5, 2018
P3, N=380, Recruiting, Sponsor: Avanir Pharmaceuticals
N=12 --> 1 | Recruiting --> Terminated; The study was terminated prematurely because of difficulty with recruiting. Trial primary completion date: Jul 2018 --> Apr 2019
- || deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial primary completion date: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury (clinicaltrials.gov) - Jan 5, 2018
P2, N=150, Recruiting, Sponsor: Avanir Pharmaceuticals
Trial primary completion date: Jul 2018 --> Apr 2019 Trial primary completion date: Dec 2019 --> Jun 2020
- |||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial completion, Enrollment change: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia (clinicaltrials.gov) - Oct 6, 2017
P2, N=145, Completed, Sponsor: Avanir Pharmaceuticals
Trial primary completion date: Dec 2019 --> Jun 2020 Active, not recruiting --> Completed | N=120 --> 145
- |||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury (clinicaltrials.gov) - Jun 14, 2017
P2, N=150, Recruiting, Sponsor: Avanir Pharmaceuticals
Active, not recruiting --> Completed | N=120 --> 145 Not yet recruiting --> Recruiting
- ||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment closed, Trial primary completion date: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia (clinicaltrials.gov) - May 17, 2017
P2, N=120, Active, not recruiting, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Aug 2017
- |||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial completion: Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment (clinicaltrials.gov) - May 15, 2017
P2, N=206, Completed, Sponsor: Avanir Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Aug 2017 Recruiting --> Completed
- ||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment change, Trial primary completion date: Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Apr 18, 2017
P3, N=700, Recruiting, Sponsor: Avanir Pharmaceuticals
Recruiting --> Completed N=550 --> 700 | Trial primary completion date: Jul 2019 --> Mar 2021
- ||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment change, Trial primary completion date: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Apr 18, 2017
P3, N=470, Recruiting, Sponsor: Avanir Pharmaceuticals
N=550 --> 700 | Trial primary completion date: Jul 2019 --> Mar 2021 N=325 --> 470 | Trial primary completion date: Jul 2018 --> Dec 2019
- ||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P2 trial: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury (clinicaltrials.gov) - Mar 29, 2017
P2, N=150, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- | deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial completion: Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts (clinicaltrials.gov) - Jul 14, 2016
P1, N=24, Completed, Sponsor: Avanir Pharmaceuticals
N=325 --> 470 | Trial primary completion date: Jul 2018 --> Dec 2019 Active, not recruiting --> Completed
- | deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open, Trial primary completion date: Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition (clinicaltrials.gov) - Jul 13, 2016
P2, N=12, Recruiting, Sponsor: Avanir Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Oct 2017
- |||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open: Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Dec 22, 2015
P3, N=550, Recruiting, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Oct 2017 Not yet recruiting --> Recruiting
- |||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open: Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Dec 22, 2015
P3, N=380, Recruiting, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type (clinicaltrials.gov) - Dec 22, 2015
P3, N=325, Recruiting, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia (clinicaltrials.gov) - Sep 14, 2015
P2, N=120, Recruiting, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P2 trial: Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition (clinicaltrials.gov) - Aug 27, 2015
P2, N=12, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment closed: Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts (clinicaltrials.gov) - Jul 13, 2015
P1, N=24, Active, not recruiting, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P2 trial: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia (clinicaltrials.gov) - Jun 23, 2015
P2, N=120, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- ||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial completion, Enrollment change: A Phase 1 Study Comparing AVP-786 With AVP-923 (clinicaltrials.gov) - Jun 23, 2015
P1, N=62, Completed, Sponsor: Avanir Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=100 --> 62
- |||||||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P3 trial: Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - May 19, 2015
P3, N=550, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- |||||||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P3 trial: Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (clinicaltrials.gov) - May 13, 2015
P3, N=380, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- |||||||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P3 trial: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type (clinicaltrials.gov) - May 13, 2015
P3, N=325, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- | deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P1 trial, New P1/2 trial: Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts (clinicaltrials.gov) - Mar 31, 2015
P1, N=24, Recruiting, Sponsor: Avanir Pharmaceuticals
- |||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Enrollment open, Trial primary completion date: Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment (clinicaltrials.gov) - Jan 30, 2015
P2, N=200, Recruiting, Sponsor: Avanir Pharmaceuticals
Active, not recruiting --> Completed | N=100 --> 62 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Mar 2016
- ||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P1 trial: A Phase 1 Study Comparing AVP-786 With AVP-923 (clinicaltrials.gov) - Jan 13, 2015
P1, N=100, Active, not recruiting, Sponsor: Avanir Pharmaceuticals
- ||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P1 trial: A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers (clinicaltrials.gov) - Jun 26, 2014
P1, N=56, Completed, Sponsor: Avanir Pharmaceuticals
- ||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P1 trial: A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects (clinicaltrials.gov) - Jun 26, 2014
P1, N=56, Completed, Sponsor: Avanir Pharmaceuticals
- ||||| deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P2 trial: Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment (clinicaltrials.gov) - Jun 1, 2014
P2, N=200, Not yet recruiting, Sponsor: Avanir Pharmaceuticals
- | deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
Trial completion: Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers (clinicaltrials.gov) - Jun 23, 2013
P1, N=48, Completed, Sponsor: Avanir Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Mar 2016 Active, not recruiting --> Completed
- | deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
New P1 trial: Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers (clinicaltrials.gov) - Feb 7, 2013
P1, N=48, Completed, Sponsor: Avanir Pharmaceuticals